Phio Pharmaceuticals Corp. Common Stock (PHIO)

Price$1.13

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-22.65%

Price vs S&P 500 (4W)-7.60%

VGM Score43.84

Market Capitalization$12.90M

All Metrics

Book Value / Share (Quarterly)$1.42

P/TBV (Annual)0.21x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.92

Price vs S&P 500 (YTD)-5.22%

Net Profit Margin (TTM)-3935.71%

EPS (TTM)$-1.49

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-1.49

EPS (Annual)$-9.05

ROI (Annual)-151.39%

Net Profit Margin (5Y Avg)-38214.76%

Cash / Share (Quarterly)$1.47

ROA (Last FY)-124.61%

EBITD / Share (TTM)$-1.47

ROE (5Y Avg)-105.54%

Operating Margin (TTM)-3957.14%

Cash Flow / Share (Annual)$-0.69

P/B Ratio0.78x

P/B Ratio (Quarterly)0.86x

Net Income / Employee (Annual)$-1,191,700

EV / Revenue (TTM)-29.54x

Net Interest Coverage (TTM)-1328.00x

ROA (TTM)-70.87%

EPS Incl Extra (Annual)$-9.05

Current Ratio (Annual)16.03x

Quick Ratio (Quarterly)17.93x

3-Month Avg Trading Volume2.61M

52-Week Price Return-45.59%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.13

P/S Ratio (Annual)644.76x

Asset Turnover (Annual)0.00x

52-Week High$4.19

Operating Margin (5Y Avg)-39948.09%

EPS Excl Extra (Annual)$-9.05

CapEx CAGR (5Y)-9.71%

Tangible BV CAGR (5Y)42.68%

26-Week Price Return-6.72%

Quick Ratio (Annual)15.69x

13-Week Price Return3.74%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)18.32x

Enterprise Value$-4.14M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-42.30%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-44550.00%

Cash / Share (Annual)$1.81

3-Month Return Std Dev59.96%

Net Income / Employee (TTM)$-1,822,000

ROE (Last FY)-151.39%

EPS Basic Excl Extra (Annual)$-9.05

Receivables Turnover (TTM)0.33x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.49

ROI (TTM)-77.34%

P/S Ratio (TTM)92.11x

Pretax Margin (5Y Avg)-39834.76%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$9.52

Price vs S&P 500 (52W)-73.79%

Year-to-Date Return5.71%

5-Day Price Return1.83%

EPS Normalized (Annual)$-9.05

ROA (5Y Avg)-88.07%

Net Profit Margin (Annual)-44550.00%

Month-to-Date Return-9.02%

Cash Flow / Share (TTM)$-7.19

EBITD / Share (Annual)$-9.35

Operating Margin (Annual)-44950.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-105.31%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.49

P/TBV (Quarterly)0.32x

P/B Ratio (Annual)0.56x

Pretax Margin (TTM)-3935.71%

Book Value / Share (Annual)$1.73

Price vs S&P 500 (13W)-6.01%

Beta0.80x

Revenue / Share (TTM)$0.00

ROE (TTM)-77.34%

52-Week Low$0.81

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PHIOPhio Pharmaceuticals Corp. Common Stock	—	—	C	$1.13
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its proprietary INTASYL RNA gene silencing technology to enhance immune cells' ability to kill tumor cells. The platform precisely targets proteins that suppress anti-cancer immunity without requiring specialized drug delivery systems. The company's pipeline includes candidates PH-762 and PH-894, with all operations based in the United States.